Multiple biochemical markers in patients with gynecologic malignancies

Area of Science:

• Gynecologic Oncology
• Clinical Chemistry
• Tumor Marker Detection

Background:

• Gynecologic malignancies represent a significant health concern.
• Tumor markers such as CEA, AFP, and hCG are used in cancer diagnostics.
• Understanding the role of these markers in gynecologic diseases is crucial for patient management.

Purpose of the Study:

• To investigate the diagnostic utility of plasma carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and human chorionic gonadotropin (hCG) in gynecologic malignancies.
• To correlate antigen levels with specific gynecologic tumor types, differentiation, and stage.
• To assess the changes in antigen levels following therapy.

Main Methods:

• Plasma levels of CEA, AFP, and hCG were measured.
• A cohort of 253 patients with gynecologic malignancies and 317 with benign gynecologic diseases were analyzed.
• Statistical analysis was performed to compare antigen levels between cancer patients and controls, and to correlate with tumor characteristics.

Main Results:

• Significantly higher plasma concentrations of CEA, AFP, and hCG were observed in patients with invasive gynecologic cancers compared to controls (p < 0.001).
• CEA was the most frequently elevated marker, followed by AFP and hCG.
• Over 85% of ovarian and cervical cancer patients showed elevated markers pre-therapy, with specific antigens correlating to tumor histology (e.g., CEA in mucinous adenocarcinomas, AFP in germ cell tumors, hCG in serous cystadenocarcinomas).
• Antigen levels correlated with tumor differentiation and stage.
• Plasma antigen levels generally normalized 8-12 weeks post-therapy.

Conclusions:

• Plasma CEA, AFP, and hCG are valuable biomarkers for detecting gynecologic malignancies.
• Specific antigen profiles can aid in identifying tumor types and stages.
• Monitoring these markers aids in assessing treatment response and disease recurrence.